Currently, combining immunogenic cell death (ICD) in cancer cells with anti‐PD‐1/PD‐L1 treatment enhances immune therapy by activating the T cell‐based immune system and reinforcing the antitumor immune response, ultimately leading to effective tumour therapy in vivo.8 The gene discussed is PDCD1; the disease is cancer.